A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies

药代动力学 医学 耐受性 不利影响 毒性 转氨酶 内科学 胃肠病学 药理学 泌尿科 化学 生物化学
作者
D. Ross Camidge,Roy S. Herbst,Michael Gordon,S. Gail Eckhardt,Razelle Kurzrock,B. Durbin,J. Ing,Tanyifor M. Tohnya,Jason A. Sager,Avi Ashkenazi,Gordon L. Bray,David S. Mendelson
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:16 (4): 1256-1263 被引量:149
标识
DOI:10.1158/1078-0432.ccr-09-1267
摘要

Abstract Purpose: PRO95780 is a fully human IgG1 monoclonal antibody that triggers the extrinsic apoptosis pathway through death receptor 5. This first-in-human study assessed the safety, tolerability, pharmacokinetics, and any early evidence of efficacy of PRO95780 in patients with advanced malignancies. Experimental Design: Target concentrations were predicted to occur at 10 mg/kg. Patients received up to eight cycles of PRO95780 i.v. using a 3+3 dose escalation design at 1 to 20 mg/kg every 14 days (every 28 days in cycle 1; stage 1), with cohort expansion at either the maximum tolerated dose or 10 mg/kg, whichever was lower (stage 2). Patients were evaluated for response every other cycle. Results: The maximum tolerated dose was not reached within this study. Four (8%) of 50 patients reported adverse events of greater than grade 2 at least possibly related to PRO95780, including 2 patients with reversible grade 3 transaminase elevation. The mean terminal half-life was 8.8 to 19.3 days, with dose-dependent increases in exposure (peak plasma concentration and area under the concentration) across 1 to 15 mg/kg. Most patients treated with 10 mg/kg or above achieved trough concentration above the target efficacious concentration at day 15 with moderate accumulation after multiple doses. No objective responses occurred, although three minor responses were observed in patients with colorectal and granulosa cell ovarian cancers (each treated with 4 mg/kg) and chondrosarcoma (10 mg/kg). Conclusions: PRO95780 is safe and well tolerated at doses up to 20 mg/kg. Evidence of activity was noted in several different tumor types at 4 and 10 mg/kg. Pharmacokinetic analysis supports a dosing regimen of 10 to 15 mg/kg every 2 to 3 weeks. Clin Cancer Res; 16(4); 1256–63
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_LMyozL完成签到 ,获得积分10
2秒前
俏皮的语芹完成签到,获得积分20
3秒前
4秒前
紫薯魏完成签到,获得积分10
5秒前
zxc完成签到,获得积分10
6秒前
8秒前
杨是个羊完成签到,获得积分10
8秒前
11秒前
随遇而安完成签到,获得积分10
13秒前
浮三白发布了新的文献求助10
14秒前
15秒前
万能图书馆应助静静子采纳,获得10
18秒前
赘婿应助农大彭于晏采纳,获得10
20秒前
山茶完成签到,获得积分20
20秒前
ltyuli完成签到,获得积分10
23秒前
27秒前
华仔应助山茶采纳,获得10
28秒前
尹冰之完成签到,获得积分10
29秒前
科目三应助农大彭于晏采纳,获得10
29秒前
浮三白完成签到,获得积分10
29秒前
猫头鹰完成签到,获得积分10
30秒前
31秒前
猫头鹰发布了新的文献求助100
33秒前
韩涵完成签到 ,获得积分10
34秒前
桐桐应助cui采纳,获得10
35秒前
仔仔仔平发布了新的文献求助10
37秒前
ltyuli发布了新的文献求助10
37秒前
41秒前
41秒前
Russell完成签到,获得积分20
44秒前
44秒前
汪汪发布了新的文献求助10
46秒前
LRxxx完成签到 ,获得积分10
46秒前
Russell发布了新的文献求助100
47秒前
天天快乐应助科研通管家采纳,获得10
48秒前
星辰大海应助科研通管家采纳,获得10
48秒前
48秒前
领导范儿应助科研通管家采纳,获得10
48秒前
shinysparrow应助科研通管家采纳,获得10
48秒前
所所应助科研通管家采纳,获得20
48秒前
高分求助中
请在求助之前详细阅读求助说明!!!! 20000
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
The Three Stars Each: The Astrolabes and Related Texts 900
Yuwu Song, Biographical Dictionary of the People's Republic of China 700
[Lambert-Eaton syndrome without calcium channel autoantibodies] 520
Bernd Ziesemer - Maos deutscher Topagent: Wie China die Bundesrepublik eroberte 500
A radiographic standard of reference for the growing knee 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2471562
求助须知:如何正确求助?哪些是违规求助? 2138113
关于积分的说明 5448377
捐赠科研通 1862072
什么是DOI,文献DOI怎么找? 926040
版权声明 562747
科研通“疑难数据库(出版商)”最低求助积分说明 495308